Harrow, Inc. introduced VEVYE Access for All, a new initiative aimed at expanding access and affordability for its dry eye disease treatment, VEVYE (cyclosporine ophthalmic solution) 0.1%. The program, available through Harrow's PhilRx specialty pharmacy partner, guarantees access to VEVYE for eligible patients and health plans for $59 per bottle.
This groundbreaking program is designed to eliminate common access barriers such as prior authorization and reimbursement delays, as well as offering free home delivery and a money-back guarantee. Patients can choose to use their insurance coverage or opt for Harrow's affordable cash price, simplifying the process for both patients and prescribers.
Mark L. Baum, CEO of Harrow, stated that the program's success lies in lowering costs to patients and removing the burden of access obstacles for prescribers. This initiative is expected to drive increased adoption of VEVYE by ensuring patients receive their prescribed treatment at an affordable price without insurance hassles.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.